IBRX Stock Analysis: Buy, Sell, or Hold?
IBRX - ImmunityBio, Inc. Common Stock
$7.18
0.00 (0.07%)
▲
5d:
+2.65%
30d:
-23.99%
90d:
+0.91%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 04, 2026
TODAY
Smart Money Accumulation
None View Scanner →
Strength: 8.7/10
Get Alerted When IBRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IBRX trading at deep discount. Market pricing in -3.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: IBRX trading at deep discount. Market pricing in -3.6% annual earnings decline, creating value opportunity for patient investors.
In-depth Analysis How we analyze
Valuation Analysis: IBRX is currently trading at $7.17, which is considered oversold relative to its 30-day fair value range of $7.20 to $8.67. From a valuation perspective, the stock is trading at a discount (Forward PE: 119.5) compared to its historical average (133.4). Remarkably, the market is currently pricing in an annual earnings decline of 3.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $6.65, while resistance sits at $8.14.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.75 (+77.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IBRX is in a downtrend. Immediate support is located at $6.65, while resistance sits at $8.14.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $12.75 (+77.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.20 -
$8.67
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 77.8% below Wall St target ($12.75)
Trading Range Analysis
30-Day Trading Range
$7.20 -
$8.67
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.65
Resistance Level
$8.14
Current Trend
Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
119.50
Wall Street Target
$12.75
(+77.8%)
Revenue Growth (YoY)
167.6%
Valuation Discount vs History
-3.6% cheaper
PE vs Historical
119.5 vs 133.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.6%
(market-implied from PE analysis)
1-Year Target
$6.91
(-4%)
2-Year Target
$6.66
(-7%)
3-Year Target
$6.42
(-10%)
3-Yr Target (if PE normalizes)
(PE: 120→133)
$7.17
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 119.5 to 133.4
Stabilization Target:
$8.00
(+11.6%)
PE Expansion Potential:
+11.6%
Share & Embed Analysis
Last updated: August 03, 2026 12:50 PM ET
Data refreshes hourly during market hours. Next update: 1:50 PM
Data refreshes hourly during market hours. Next update: 1:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IBRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barry J Simon
SELL
75000 shares
2026-02-24
Barry J Simon
SELL
165000 shares
2026-02-23
Christobel Selecky
SELL
25000 shares
2026-02-23
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
Advanced IBRX Option Strategies
Professional options setups generated by AI based on today's IBRX price and gamma walls.
